Trial Outcomes & Findings for Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema (NCT NCT00444600)
NCT ID: NCT00444600
Last Updated: 2019-10-07
Results Overview
Change in best correct visual acuity letter score from baseline to one year as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0.
Recruitment status
COMPLETED
Study phase
PHASE3
Target enrollment
691 participants
Primary outcome timeframe
from baseline to 1 Year
Results posted on
2019-10-07
Participant Flow
Fifty two academic and community based sites across the United States recruited 691 study participants from March 2007 to December 2008.
Participants with two study eyes enrolled each eye in a different treatment group. Therefore, each treatment group/arm includes no more than one study eye for a given participant, and thus the numbers of eyes is equal to the number of participants in each arm.
Participant milestones
| Measure |
Sham+Prompt Laser
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
293
|
187
|
188
|
186
|
|
Overall Study
COMPLETED
|
274
|
171
|
178
|
176
|
|
Overall Study
NOT COMPLETED
|
19
|
16
|
10
|
10
|
Reasons for withdrawal
| Measure |
Sham+Prompt Laser
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Overall Study
Death
|
7
|
5
|
3
|
2
|
|
Overall Study
Dropped
|
11
|
11
|
7
|
7
|
|
Overall Study
Missed visit
|
1
|
0
|
0
|
1
|
Baseline Characteristics
Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema
Baseline characteristics by cohort
| Measure |
Sham+Prompt Laser
n=293 Participants
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=187 Participants
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=188 Participants
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=186 Participants
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
Total
n=854 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Visual Acuity Letter Score (approximate Snellen equivalent) by randomization strata
≤65 (20/50 or worse)
|
147 Eyes
n=99 Participants
|
92 Eyes
n=107 Participants
|
93 Eyes
n=206 Participants
|
93 Eyes
n=7 Participants
|
425 Eyes
n=31 Participants
|
|
Age, Continuous
|
63 years
n=99 Participants
|
62 years
n=107 Participants
|
64 years
n=206 Participants
|
62 years
n=7 Participants
|
63 years
n=31 Participants
|
|
Sex: Female, Male
Female
|
123 Participants
n=99 Participants
|
85 Participants
n=107 Participants
|
78 Participants
n=206 Participants
|
86 Participants
n=7 Participants
|
372 Participants
n=31 Participants
|
|
Sex: Female, Male
Male
|
170 Participants
n=99 Participants
|
102 Participants
n=107 Participants
|
110 Participants
n=206 Participants
|
100 Participants
n=7 Participants
|
482 Participants
n=31 Participants
|
|
Race/Ethnicity, Customized
White
|
202 Participants
n=99 Participants
|
131 Participants
n=107 Participants
|
134 Participants
n=206 Participants
|
134 Participants
n=7 Participants
|
601 Participants
n=31 Participants
|
|
Race/Ethnicity, Customized
African American
|
51 Participants
n=99 Participants
|
30 Participants
n=107 Participants
|
25 Participants
n=206 Participants
|
32 Participants
n=7 Participants
|
138 Participants
n=31 Participants
|
|
Race/Ethnicity, Customized
Hispanic or Latino
|
34 Participants
n=99 Participants
|
21 Participants
n=107 Participants
|
25 Participants
n=206 Participants
|
15 Participants
n=7 Participants
|
95 Participants
n=31 Participants
|
|
Race/Ethnicity, Customized
Asian
|
4 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
2 Participants
n=206 Participants
|
4 Participants
n=7 Participants
|
11 Participants
n=31 Participants
|
|
Race/Ethnicity, Customized
Native Hawaiian/Other Pacific Islander
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=31 Participants
|
|
Race/Ethnicity, Customized
More than one race
|
1 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
0 Participants
n=7 Participants
|
3 Participants
n=31 Participants
|
|
Race/Ethnicity, Customized
Unknown/not reported
|
1 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
1 Participants
n=7 Participants
|
5 Participants
n=31 Participants
|
|
Visual Acuity Letter Score (approximate Snellen equivalent) by randomization strata
≥66 (better than 20/50)
|
146 Eyes
n=99 Participants
|
95 Eyes
n=107 Participants
|
95 Eyes
n=206 Participants
|
93 Eyes
n=7 Participants
|
429 Eyes
n=31 Participants
|
|
Classification of diabetic macular edema
Predominantly focal
|
78 Eyes
n=99 Participants
|
60 Eyes
n=107 Participants
|
68 Eyes
n=206 Participants
|
53 Eyes
n=7 Participants
|
259 Eyes
n=31 Participants
|
|
Classification of diabetic macular edema
Neither predominantly focal or diffuse
|
71 Eyes
n=99 Participants
|
46 Eyes
n=107 Participants
|
41 Eyes
n=206 Participants
|
48 Eyes
n=7 Participants
|
206 Eyes
n=31 Participants
|
|
Classification of diabetic macular edema
Predominantly diffuse
|
144 Eyes
n=99 Participants
|
81 Eyes
n=107 Participants
|
79 Eyes
n=206 Participants
|
85 Eyes
n=7 Participants
|
389 Eyes
n=31 Participants
|
|
Number of study eyes
1 study eye
|
130 Participants
n=99 Participants
|
131 Participants
n=107 Participants
|
132 Participants
n=206 Participants
|
135 Participants
n=7 Participants
|
528 Participants
n=31 Participants
|
|
Number of study eyes
2 study eyes
|
163 Participants
n=99 Participants
|
56 Participants
n=107 Participants
|
56 Participants
n=206 Participants
|
51 Participants
n=7 Participants
|
326 Participants
n=31 Participants
|
|
Diabetes Type
Type 1
|
25 Participants
n=99 Participants
|
11 Participants
n=107 Participants
|
15 Participants
n=206 Participants
|
14 Participants
n=7 Participants
|
65 Participants
n=31 Participants
|
|
Diabetes Type
Type 2
|
260 Participants
n=99 Participants
|
172 Participants
n=107 Participants
|
170 Participants
n=206 Participants
|
166 Participants
n=7 Participants
|
768 Participants
n=31 Participants
|
|
Diabetes Type
Uncertain
|
8 Participants
n=99 Participants
|
4 Participants
n=107 Participants
|
3 Participants
n=206 Participants
|
6 Participants
n=7 Participants
|
21 Participants
n=31 Participants
|
|
Duration of diabetes
|
16 Years
n=99 Participants
|
18 Years
n=107 Participants
|
17 Years
n=206 Participants
|
17 Years
n=7 Participants
|
16 Years
n=31 Participants
|
|
HbA1c
|
7.3 Percentage
n=99 Participants
|
7.3 Percentage
n=107 Participants
|
7.5 Percentage
n=206 Participants
|
7.4 Percentage
n=7 Participants
|
7.3 Percentage
n=31 Participants
|
|
Prior cardiovascular event
Yes
|
93 Participants
n=99 Participants
|
66 Participants
n=107 Participants
|
61 Participants
n=206 Participants
|
61 Participants
n=7 Participants
|
281 Participants
n=31 Participants
|
|
Prior cardiovascular event
No
|
200 Participants
n=99 Participants
|
121 Participants
n=107 Participants
|
127 Participants
n=206 Participants
|
125 Participants
n=7 Participants
|
573 Participants
n=31 Participants
|
|
Hypertension
Yes
|
240 Participants
n=99 Participants
|
154 Participants
n=107 Participants
|
156 Participants
n=206 Participants
|
148 Participants
n=7 Participants
|
698 Participants
n=31 Participants
|
|
Hypertension
No
|
53 Participants
n=99 Participants
|
33 Participants
n=107 Participants
|
32 Participants
n=206 Participants
|
38 Participants
n=7 Participants
|
156 Participants
n=31 Participants
|
|
Prior Panretinal Photocoagulation
Yes
|
48 Eyes
n=99 Participants
|
36 Eyes
n=107 Participants
|
31 Eyes
n=206 Participants
|
37 Eyes
n=7 Participants
|
152 Eyes
n=31 Participants
|
|
Prior Panretinal Photocoagulation
No
|
245 Eyes
n=99 Participants
|
151 Eyes
n=107 Participants
|
157 Eyes
n=206 Participants
|
149 Eyes
n=7 Participants
|
702 Eyes
n=31 Participants
|
|
Prior treatment for diabetic macular edema
No
|
105 Eyes
n=99 Participants
|
74 Eyes
n=107 Participants
|
74 Eyes
n=206 Participants
|
61 Eyes
n=7 Participants
|
314 Eyes
n=31 Participants
|
|
Prior treatment for diabetic macular edema
Yes
|
188 Eyes
n=99 Participants
|
113 Eyes
n=107 Participants
|
114 Eyes
n=206 Participants
|
125 Eyes
n=7 Participants
|
540 Eyes
n=31 Participants
|
|
Prior laser for diabetic macular edema
Yes
|
173 Eyes
n=99 Participants
|
101 Eyes
n=107 Participants
|
101 Eyes
n=206 Participants
|
114 Eyes
n=7 Participants
|
489 Eyes
n=31 Participants
|
|
Prior laser for diabetic macular edema
No
|
120 Eyes
n=99 Participants
|
86 Eyes
n=107 Participants
|
87 Eyes
n=206 Participants
|
72 Eyes
n=7 Participants
|
365 Eyes
n=31 Participants
|
|
Prior IVT for diabetic macular edema
Yes
|
39 Eyes
n=99 Participants
|
22 Eyes
n=107 Participants
|
36 Eyes
n=206 Participants
|
31 Eyes
n=7 Participants
|
128 Eyes
n=31 Participants
|
|
Prior IVT for diabetic macular edema
No
|
254 Eyes
n=99 Participants
|
165 Eyes
n=107 Participants
|
152 Eyes
n=206 Participants
|
155 Eyes
n=7 Participants
|
726 Eyes
n=31 Participants
|
|
Prior vitrectomy for diabetic macular edema
Yes
|
15 Eyes
n=99 Participants
|
7 Eyes
n=107 Participants
|
5 Eyes
n=206 Participants
|
12 Eyes
n=7 Participants
|
39 Eyes
n=31 Participants
|
|
Prior vitrectomy for diabetic macular edema
No
|
278 Eyes
n=99 Participants
|
180 Eyes
n=107 Participants
|
183 Eyes
n=206 Participants
|
174 Eyes
n=7 Participants
|
815 Eyes
n=31 Participants
|
|
Prior peribulbar triamcinolone for diabetic macular edema
Yes
|
12 Eyes
n=99 Participants
|
9 Eyes
n=107 Participants
|
5 Eyes
n=206 Participants
|
5 Eyes
n=7 Participants
|
31 Eyes
n=31 Participants
|
|
Prior peribulbar triamcinolone for diabetic macular edema
No
|
281 Eyes
n=99 Participants
|
178 Eyes
n=107 Participants
|
183 Eyes
n=206 Participants
|
181 Eyes
n=7 Participants
|
823 Eyes
n=31 Participants
|
|
Prior anti-VEGF for diabetic macular edema
Yes
|
24 Eyes
n=99 Participants
|
24 Eyes
n=107 Participants
|
21 Eyes
n=206 Participants
|
20 Eyes
n=7 Participants
|
89 Eyes
n=31 Participants
|
|
Prior anti-VEGF for diabetic macular edema
No
|
269 Eyes
n=99 Participants
|
163 Eyes
n=107 Participants
|
167 Eyes
n=206 Participants
|
166 Eyes
n=7 Participants
|
765 Eyes
n=31 Participants
|
|
Intraocular pressure
|
16 mmHg
n=99 Participants
|
16 mmHg
n=107 Participants
|
16 mmHg
n=206 Participants
|
16 mmHg
n=7 Participants
|
16 mmHg
n=31 Participants
|
|
Currently on intraocular pressure lowering medicine for glaucoma or ocular hypertension
Yes
|
5 Eyes
n=99 Participants
|
6 Eyes
n=107 Participants
|
4 Eyes
n=206 Participants
|
2 Eyes
n=7 Participants
|
17 Eyes
n=31 Participants
|
|
Currently on intraocular pressure lowering medicine for glaucoma or ocular hypertension
No
|
288 Eyes
n=99 Participants
|
181 Eyes
n=107 Participants
|
184 Eyes
n=206 Participants
|
184 Eyes
n=7 Participants
|
837 Eyes
n=31 Participants
|
|
Lens status
Phakic
|
192 Eyes
n=99 Participants
|
131 Eyes
n=107 Participants
|
134 Eyes
n=206 Participants
|
124 Eyes
n=7 Participants
|
581 Eyes
n=31 Participants
|
|
Lens status
Anterior Chamber Intraocular Lense
|
3 Eyes
n=99 Participants
|
1 Eyes
n=107 Participants
|
1 Eyes
n=206 Participants
|
0 Eyes
n=7 Participants
|
5 Eyes
n=31 Participants
|
|
Lens status
Posterior Chamber Intraocular Lense
|
98 Eyes
n=99 Participants
|
55 Eyes
n=107 Participants
|
53 Eyes
n=206 Participants
|
62 Eyes
n=7 Participants
|
268 Eyes
n=31 Participants
|
|
E-ETDRS Visual Acuity Letter Score
|
65 Letter Score
n=99 Participants
|
66 Letter Score
n=107 Participants
|
66 Letter Score
n=206 Participants
|
66 Letter Score
n=7 Participants
|
66 Letter Score
n=31 Participants
|
|
Central subfield thickness on optical coherence tomography
|
407 microns
n=99 Participants
|
371 microns
n=107 Participants
|
382 microns
n=206 Participants
|
374 microns
n=7 Participants
|
381 microns
n=31 Participants
|
|
Retinal volume on optical coherence tomography
|
8.7 microns
n=99 Participants
|
8.4 microns
n=107 Participants
|
8.4 microns
n=206 Participants
|
8.5 microns
n=7 Participants
|
8.5 microns
n=31 Participants
|
|
Optical coherence tomography cystoid abnormality
No evidence
|
19 Eyes
n=99 Participants
|
13 Eyes
n=107 Participants
|
12 Eyes
n=206 Participants
|
8 Eyes
n=7 Participants
|
52 Eyes
n=31 Participants
|
|
Optical coherence tomography cystoid abnormality
Questionable or definite
|
274 Eyes
n=99 Participants
|
171 Eyes
n=107 Participants
|
174 Eyes
n=206 Participants
|
177 Eyes
n=7 Participants
|
796 Eyes
n=31 Participants
|
|
Optical coherence tomography cystoid abnormality
Cannot grade or missing
|
0 Eyes
n=99 Participants
|
3 Eyes
n=107 Participants
|
2 Eyes
n=206 Participants
|
1 Eyes
n=7 Participants
|
6 Eyes
n=31 Participants
|
|
Optical coherence tomography subretinal fluid present
No evidence
|
222 Eyes
n=99 Participants
|
149 Eyes
n=107 Participants
|
140 Eyes
n=206 Participants
|
146 Eyes
n=7 Participants
|
657 Eyes
n=31 Participants
|
|
Optical coherence tomography subretinal fluid present
Questionable or definite
|
70 Eyes
n=99 Participants
|
36 Eyes
n=107 Participants
|
45 Eyes
n=206 Participants
|
38 Eyes
n=7 Participants
|
189 Eyes
n=31 Participants
|
|
Optical coherence tomography subretinal fluid present
Cannot grade
|
1 Eyes
n=99 Participants
|
2 Eyes
n=107 Participants
|
3 Eyes
n=206 Participants
|
2 Eyes
n=7 Participants
|
8 Eyes
n=31 Participants
|
|
ETDRS retinopathy severity level (ETDRS description)
Diabetic retinopathy absent
|
5 Eyes
n=99 Participants
|
4 Eyes
n=107 Participants
|
3 Eyes
n=206 Participants
|
1 Eyes
n=7 Participants
|
13 Eyes
n=31 Participants
|
|
ETDRS retinopathy severity level (ETDRS description)
Minimal non-proliferative DR
|
2 Eyes
n=99 Participants
|
2 Eyes
n=107 Participants
|
3 Eyes
n=206 Participants
|
3 Eyes
n=7 Participants
|
10 Eyes
n=31 Participants
|
|
ETDRS retinopathy severity level (ETDRS description)
Mild to moderately severe non-proliferative DR
|
171 Eyes
n=99 Participants
|
103 Eyes
n=107 Participants
|
107 Eyes
n=206 Participants
|
95 Eyes
n=7 Participants
|
476 Eyes
n=31 Participants
|
|
ETDRS retinopathy severity level (ETDRS description)
Severe non-proliferative DR
|
22 Eyes
n=99 Participants
|
16 Eyes
n=107 Participants
|
11 Eyes
n=206 Participants
|
15 Eyes
n=7 Participants
|
64 Eyes
n=31 Participants
|
|
ETDRS retinopathy severity level (ETDRS description)
Scars of full or partial PRP present;PDR absent
|
38 Eyes
n=99 Participants
|
30 Eyes
n=107 Participants
|
30 Eyes
n=206 Participants
|
29 Eyes
n=7 Participants
|
127 Eyes
n=31 Participants
|
|
ETDRS retinopathy severity level (ETDRS description)
Mild to moderate proliferative DR
|
33 Eyes
n=99 Participants
|
24 Eyes
n=107 Participants
|
22 Eyes
n=206 Participants
|
34 Eyes
n=7 Participants
|
113 Eyes
n=31 Participants
|
|
ETDRS retinopathy severity level (ETDRS description)
High risk proliferative DR
|
7 Eyes
n=99 Participants
|
4 Eyes
n=107 Participants
|
1 Eyes
n=206 Participants
|
3 Eyes
n=7 Participants
|
15 Eyes
n=31 Participants
|
|
ETDRS retinopathy severity level (ETDRS description)
Cannot grade
|
10 Eyes
n=99 Participants
|
1 Eyes
n=107 Participants
|
2 Eyes
n=206 Participants
|
4 Eyes
n=7 Participants
|
17 Eyes
n=31 Participants
|
|
ETDRS retinopathy severity level (ETDRS description)
Missing
|
5 Eyes
n=99 Participants
|
3 Eyes
n=107 Participants
|
9 Eyes
n=206 Participants
|
2 Eyes
n=7 Participants
|
19 Eyes
n=31 Participants
|
PRIMARY outcome
Timeframe: from baseline to 1 YearPopulation: For eyes without any 1-year data the last observation carried forward method was used to impute data for the primary analysis. followed intention to treat principle.
Change in best correct visual acuity letter score from baseline to one year as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0.
Outcome measures
| Measure |
Sham+Prompt Laser
n=293 Eyes
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=187 Eyes
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=188 Eyes
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=186 Eyes
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Mean Change in Visual Acuity (Letters) From Baseline to 1 Year Adjusted for Baseline Visual Acuity
|
3 Letters
Standard Deviation 13
|
9 Letters
Standard Deviation 11
|
9 Letters
Standard Deviation 12
|
4 Letters
Standard Deviation 13
|
PRIMARY outcome
Timeframe: from baseline to 1 YearPopulation: For eyes without any 1-year data the last observation carried forward method was used to impute data for the primary analysis.
Change in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method.
Outcome measures
| Measure |
Sham+Prompt Laser
n=293 Eyes
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=187 Eyes
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=188 Eyes
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=186 Eyes
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Distribution of Change in Visual Acuity (Letters) From Baseline to 1 Year
9-5 letter improvement
|
67 Eyes
|
34 Eyes
|
54 Eyes
|
32 Eyes
|
|
Distribution of Change in Visual Acuity (Letters) From Baseline to 1 Year
≥15 letter improvement
|
43 Eyes
|
57 Eyes
|
52 Eyes
|
39 Eyes
|
|
Distribution of Change in Visual Acuity (Letters) From Baseline to 1 Year
14-10 letter improvement
|
38 Eyes
|
38 Eyes
|
36 Eyes
|
22 Eyes
|
|
Distribution of Change in Visual Acuity (Letters) From Baseline to 1 Year
Same ±4 letters
|
86 Eyes
|
38 Eyes
|
35 Eyes
|
54 Eyes
|
|
Distribution of Change in Visual Acuity (Letters) From Baseline to 1 Year
5-9 letters worse
|
20 Eyes
|
14 Eyes
|
5 Eyes
|
12 Eyes
|
|
Distribution of Change in Visual Acuity (Letters) From Baseline to 1 Year
10-14 letters worse
|
16 Eyes
|
3 Eyes
|
2 Eyes
|
12 Eyes
|
|
Distribution of Change in Visual Acuity (Letters) From Baseline to 1 Year
≥15 letters worse
|
23 Eyes
|
3 Eyes
|
4 Eyes
|
15 Eyes
|
PRIMARY outcome
Timeframe: from baseline to 1 YearOutcome measures
| Measure |
Sham+Prompt Laser
n=293 Eyes
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=187 Eyes
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=188 Eyes
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=186 Eyes
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Change in Visual Acuity From Baseline to 1 Year Among Eyes That Were Pseudophakic at Baseline
Not pseudophakic at baseline
|
2 Letters
Standard Deviation 13
|
9 Letters
Standard Deviation 10
|
10 Letters
Standard Deviation 14
|
2 Letters
Standard Deviation 14
|
|
Change in Visual Acuity From Baseline to 1 Year Among Eyes That Were Pseudophakic at Baseline
Pseudophakic at baseline
|
4 Letters
Standard Deviation 14
|
8 Letters
Standard Deviation 12
|
7 Letters
Standard Deviation 9
|
8 Letters
Standard Deviation 9
|
PRIMARY outcome
Timeframe: from baseline to 1 YearOutcome measures
| Measure |
Sham+Prompt Laser
n=293 Participants
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=187 Participants
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=188 Participants
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=186 Participants
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Change in Visual Acuity From Baseline to 1 Year Among Eyes That Had Prior Treatment for Diabetic Macular Edema
No
|
2 Letters
Standard Deviation 14
|
9 Letters
Standard Deviation 12
|
11 Letters
Standard Deviation 13
|
3 Letters
Standard Deviation 13
|
|
Change in Visual Acuity From Baseline to 1 Year Among Eyes That Had Prior Treatment for Diabetic Macular Edema
Yes
|
3 Letters
Standard Deviation 13
|
9 Letters
Standard Deviation 10
|
8 Letters
Standard Deviation 12
|
5 Letters
Standard Deviation 13
|
PRIMARY outcome
Timeframe: from baseline to 1 YearChange in best correct visual acuity letter score as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0.
Outcome measures
| Measure |
Sham+Prompt Laser
n=293 Participants
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=187 Participants
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=188 Participants
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=186 Participants
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Change in Visual Acuity From Baseline to 1 Year Grouped by Baseline Visual Acuity Letter Score
≥66 (better than 20/50)
|
1 Letters
Standard Deviation 12
|
6 Letters
Standard Deviation 10
|
5 Letters
Standard Deviation 13
|
1 Letters
Standard Deviation 11
|
|
Change in Visual Acuity From Baseline to 1 Year Grouped by Baseline Visual Acuity Letter Score
≤65 (20/50 or worse)
|
5 Letters
Standard Deviation 14
|
12 Letters
Standard Deviation 11
|
13 Letters
Standard Deviation 10
|
7 Letters
Standard Deviation 14
|
PRIMARY outcome
Timeframe: from baseline to 1 YearChange in best correct visual acuity letter score from baseline to one year as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0.
Outcome measures
| Measure |
Sham+Prompt Laser
n=293 Eyes
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=187 Eyes
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=188 Eyes
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=186 Eyes
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Change in Visual Acuity From Baseline to 1 Year Grouped by Optical Coherence Tomography Central Subfield Thickness
<400 microns
|
3 Letters
Standard Deviation 11
|
7 Letters
Standard Deviation 11
|
7 Letters
Standard Deviation 12
|
3 Letters
Standard Deviation 12
|
|
Change in Visual Acuity From Baseline to 1 Year Grouped by Optical Coherence Tomography Central Subfield Thickness
≥400 microns
|
3 Letters
Standard Deviation 15
|
11 Letters
Standard Deviation 10
|
11 Letters
Standard Deviation 13
|
6 Letters
Standard Deviation 14
|
PRIMARY outcome
Timeframe: from baseline to 1 YearChange in best correct visual acuity letter score from baseline to one year as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0.
Outcome measures
| Measure |
Sham+Prompt Laser
n=293 eyes
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=187 eyes
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=188 eyes
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=186 eyes
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Change in Visual Acuity From Baseline to 1 Year Grouped by Diabetic Retinopathy Severity
Moderately severe non-proliferative DR or better
|
3 Letters
Standard Deviation 13
|
10 Letters
Standard Deviation 11
|
9 Letters
Standard Deviation 12
|
3 Letters
Standard Deviation 14
|
|
Change in Visual Acuity From Baseline to 1 Year Grouped by Diabetic Retinopathy Severity
Severe non-proliferative DR or worse
|
2 Letters
Standard Deviation 15
|
8 Letters
Standard Deviation 10
|
9 Letters
Standard Deviation 13
|
5 Letters
Standard Deviation 12
|
PRIMARY outcome
Timeframe: from baseline to 1 YearChange in best correct visual acuity letter score from baseline to one year as measured by a certified tester using an electronic visual acuity testing machine based on the Early Treatment Diabetic Retinopathy Study (ETDRS) method. A positive change denotes an improvement. Best value on the scale 97, worst 0.
Outcome measures
| Measure |
Sham+Prompt Laser
n=293 Eyes
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=187 Eyes
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=188 Eyes
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=186 Eyes
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Change in Visual Acuity From Baseline to 1 Year Grouped by Diffuse vs. Focal Edema as Characterized by the Investigator
Typical/predominantly focal
|
3 Letters
Standard Deviation 13
|
8 Letters
Standard Deviation 11
|
8 Letters
Standard Deviation 13
|
3 Letters
Standard Deviation 11
|
|
Change in Visual Acuity From Baseline to 1 Year Grouped by Diffuse vs. Focal Edema as Characterized by the Investigator
Neither predominantly focal nor diffuse
|
2 Letters
Standard Deviation 14
|
10 Letters
Standard Deviation 9
|
8 Letters
Standard Deviation 15
|
3 Letters
Standard Deviation 13
|
|
Change in Visual Acuity From Baseline to 1 Year Grouped by Diffuse vs. Focal Edema as Characterized by the Investigator
Typical/predominantly diffuse
|
3 Letters
Standard Deviation 13
|
9 Letters
Standard Deviation 12
|
10 Letters
Standard Deviation 10
|
5 Letters
Standard Deviation 14
|
SECONDARY outcome
Timeframe: from baseline to 1 yearNegative change denotes an improvement.
Outcome measures
| Measure |
Sham+Prompt Laser
n=271 Participants
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=171 Eyes
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=175 Eyes
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=173 Eyes
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Change in Retinal Thickening of Central Subfield on Optical Coherence Tomography From Baseline to 1 Year
|
-102 microns
Standard Deviation 151
|
-131 microns
Standard Deviation 129
|
-137 microns
Standard Deviation 136
|
-127 microns
Standard Deviation 140
|
SECONDARY outcome
Timeframe: from baseline to 1 yearPopulation: Sham+prompt laser group listed median excludes 56 eyes among 163 participants with 2 study eyes that were unmasked at baseline because the participant's other eye was in the ranibizumab+deferred laser group, precluding sham injections for the study eye assigned to sham+prompt laser.
Maximum possible number of injections for each of the following groups: sham+prompt laser=13 sham injections;ranibizumab+prompt laser=13 ranibizumab injections; ranibizumab+deferred laser=13 ranibizumab injections; triamcinolone+prompt laser=4 triamcinolone injections and 9 sham injections.
Outcome measures
| Measure |
Sham+Prompt Laser
n=274 Eyes
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=171 Eyes
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=178 Eyes
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=176 Eyes
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Number of Injections in First Year
|
11 Injections
Interval 8.0 to 13.0
|
8 Injections
Interval 6.0 to 10.0
|
9 Injections
Interval 6.0 to 11.0
|
3 Injections
Interval 2.0 to 4.0
|
SECONDARY outcome
Timeframe: 1 YearPopulation: Number who completed the 1-year visit.
One eye in the sham+prompt laser group did not receive laser until post 1-year due to an adverse event unrelated to study treatment. One eye in the triamcinolone+prompt laser did not receive laser until after 1-year due to missing 2 consecutive visits at the time of required laser treatment.
Outcome measures
| Measure |
Sham+Prompt Laser
n=274 Eyes
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=171 Eyes
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=178 Eyes
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=176 Eyes
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Number of Laser Treatments Received Prior to the 1 Year Visit
0
|
1 Eyes
|
0 Eyes
|
124 Eyes
|
1 Eyes
|
|
Number of Laser Treatments Received Prior to the 1 Year Visit
1
|
35 Eyes
|
53 Eyes
|
36 Eyes
|
46 Eyes
|
|
Number of Laser Treatments Received Prior to the 1 Year Visit
2
|
75 Eyes
|
54 Eyes
|
17 Eyes
|
53 Eyes
|
|
Number of Laser Treatments Received Prior to the 1 Year Visit
3
|
107 Eyes
|
46 Eyes
|
1 Eyes
|
49 Eyes
|
|
Number of Laser Treatments Received Prior to the 1 Year Visit
4
|
56 Eyes
|
18 Eyes
|
0 Eyes
|
27 Eyes
|
SECONDARY outcome
Timeframe: 1 YearOutcome measures
| Measure |
Sham+Prompt Laser
n=274 Eyes
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=171 Eyes
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=178 Eyes
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=176 Eyes
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Percentage of Eyes Receiving Laser at the 48 Week Visit (%)
|
26 Eyes
|
16 Eyes
|
8 Eyes
|
21 Eyes
|
SECONDARY outcome
Timeframe: 1 YearOutcome measures
| Measure |
Sham+Prompt Laser
n=293 Eyes
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=187 Eyes
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=188 Eyes
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=186 Eyes
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Mean Optical Coherence Tomography Retinal Volume at 1 Year
|
8.1 mm^3
Standard Deviation 1.4
|
7.3 mm^3
Standard Deviation 1.0
|
7.4 mm^3
Standard Deviation 1.2
|
7.5 mm^3
Standard Deviation 1.3
|
SECONDARY outcome
Timeframe: from baseline to 1 YearOutcome measures
| Measure |
Sham+Prompt Laser
n=293 Eyes
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=187 Eyes
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=188 Eyes
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=186 Eyes
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Mean Change in Optical Coherence Tomography Retinal Volume From Baseline to 1 Year
|
-1.0 mm^3
Standard Deviation 1.4
|
-1.4 mm^3
Standard Deviation 1.4
|
-1.5 mm^3
Standard Deviation 1.5
|
-1.4 mm^3
Standard Deviation 1.6
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 1 YearOutcome measures
| Measure |
Sham+Prompt Laser
n=271 Eyes
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=171 Eyes
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=175 Eyes
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=173 Eyes
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Central Subfield Thickness < 250 With at Least a 25 Micron Decrease From Baseline to 1 Year
|
72 Eyes
|
91 Eyes
|
74 Eyes
|
82 Eyes
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 1 YearLogarithmic transformation of optical coherence tomography central subfield thickness is calculated by taking the log base 10 of the ratio of the central subfield thickness divided by 200 and rounding to the nearest hundredth. The change is the change in the log values.
Outcome measures
| Measure |
Sham+Prompt Laser
n=271 Eyes
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=171 Eyes
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=175 Eyes
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=173 Eyes
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Distribution of Logarithmic Transformation of Optical Coherence Tomography (LogOCT) Improvement and Worsening
≥2 step improvement
|
81 Eyes
|
72 Eyes
|
71 Eyes
|
65 Eyes
|
|
Distribution of Logarithmic Transformation of Optical Coherence Tomography (LogOCT) Improvement and Worsening
≥2 step worsening
|
6 Eyes
|
1 Eyes
|
0 Eyes
|
4 Eyes
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 1 YearEach combination of treatment only counted once.
Outcome measures
| Measure |
Sham+Prompt Laser
n=293 Eyes
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=187 Eyes
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=188 Eyes
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=186 Eyes
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Eyes With Alternative Treatments Prior to the 1-year Visit
Intravitreal bevacizumab
|
3 Eyes
|
0 Eyes
|
0 Eyes
|
1 Eyes
|
|
Eyes With Alternative Treatments Prior to the 1-year Visit
Vitrectomy
|
2 Eyes
|
0 Eyes
|
0 Eyes
|
0 Eyes
|
|
Eyes With Alternative Treatments Prior to the 1-year Visit
Intravitreal bevacizumab+triamcinolone acetonide
|
4 Eyes
|
0 Eyes
|
0 Eyes
|
0 Eyes
|
|
Eyes With Alternative Treatments Prior to the 1-year Visit
Total number of eyes with alternative treatments
|
14 Eyes
|
1 Eyes
|
0 Eyes
|
1 Eyes
|
|
Eyes With Alternative Treatments Prior to the 1-year Visit
Total number of treatments applied
|
25 Eyes
|
1 Eyes
|
0 Eyes
|
1 Eyes
|
|
Eyes With Alternative Treatments Prior to the 1-year Visit
Total per protocol treatments applied
|
5 Eyes
|
1 Eyes
|
0 Eyes
|
1 Eyes
|
|
Eyes With Alternative Treatments Prior to the 1-year Visit
Total deviations from protocol treatments applied
|
9 Eyes
|
0 Eyes
|
0 Eyes
|
0 Eyes
|
|
Eyes With Alternative Treatments Prior to the 1-year Visit
Intravitreal triamcinolone acetonide
|
5 Eyes
|
0 Eyes
|
0 Eyes
|
0 Eyes
|
OTHER_PRE_SPECIFIED outcome
Timeframe: from baseline to 1 Year113 eyes had missing or ungradable photos at 1 year. Criteria are based on the ETDRS fundus photographic risk factors for the progression of diabetic retinopathy. ETDRS report no. 12. Ophthalmology 1991; 98:823-833
Outcome measures
| Measure |
Sham+Prompt Laser
n=150 Eyes
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=182 Eyes
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=80 Eyes
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Change From Moderately Severe Non-proliferative Diabetic Retinopathy or Better From Baseline to 1-year
Improved by 2 or more levels
|
6 Eyes
|
46 Eyes
|
20 Eyes
|
—
|
|
Change From Moderately Severe Non-proliferative Diabetic Retinopathy or Better From Baseline to 1-year
Worsened by 2 or more levels
|
11 Eyes
|
5 Eyes
|
2 Eyes
|
—
|
OTHER_PRE_SPECIFIED outcome
Timeframe: from baseline to 1 YearCriteria are based on the ETDRS fundus photographic risk factors for the progression of diabetic retinopathy. ETDRS report no. 12. Ophthalmology 1991; 98:823-833, ETDRS Severity Scale = Diabetic retinopathy absent, minimal non-proliferative diabetic retinopathy (PDR), mild to moderately severe non-PDR, severe non-PDR, scars of full pr partial panretinal photocoagulation present PDR absent, mild to moderate PDR, high risk PDR, cannot grade, missing.
Outcome measures
| Measure |
Sham+Prompt Laser
n=83 Eyes
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=121 Eyes
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=70 Eyes
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Change From Severe Non-proliferative Diabetic Retinopathy or Worse From Baseline to 1-year
Improved by 2 or more levels
|
10 Eyes
|
18 Eyes
|
6 Eyes
|
—
|
|
Change From Severe Non-proliferative Diabetic Retinopathy or Worse From Baseline to 1-year
Worsened by 2 or more levels
|
7 Eyes
|
1 Eyes
|
2 Eyes
|
—
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 1 YearPopulation: Study participants with 2 study eyes are assigned to the non-sham group. Multiple events within a study participant are only counted once per event.
Antiplatelet Trialists' Collaboration is a collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. MBJ 1994; 308:81-106. Nonfatal cerebrovascular accident includes ischemic or hemorrhagic or unknown events. Vascular death includes death from any potential vascular or unknown cause.
Outcome measures
| Measure |
Sham+Prompt Laser
n=130 Participants
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=375 Participants
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=186 Participants
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Cardiovascular Events According to Antiplatelet Trialists' Collaboration Through 1 Year
Nonfatal myocardial infarction
|
3 Participants
|
1 Participants
|
2 Participants
|
—
|
|
Cardiovascular Events According to Antiplatelet Trialists' Collaboration Through 1 Year
Nonfatal cerebrovascular accident
|
5 Participants
|
3 Participants
|
1 Participants
|
—
|
|
Cardiovascular Events According to Antiplatelet Trialists' Collaboration Through 1 Year
Vascular death
|
4 Participants
|
7 Participants
|
2 Participants
|
—
|
|
Cardiovascular Events According to Antiplatelet Trialists' Collaboration Through 1 Year
Any ATC cardiovascular event
|
10 Participants
|
11 Participants
|
5 Participants
|
—
|
OTHER_PRE_SPECIFIED outcome
Timeframe: 1 YearOutcome measures
| Measure |
Sham+Prompt Laser
n=293 Eyes
Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Prompt Laser
n=187 Eyes
0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
0.5 mg Ranibizumab+Deferred Laser
n=188 Eyes
0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
|
4 mg Triamcinolone+Prompt Laser
n=186 Eyes
4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
|
|---|---|---|---|---|
|
Major Ocular Adverse Events During First Year of Follow-Up
Endophthalmitis
|
1 Eyes
|
1 Eyes
|
1 Eyes
|
0 Eyes
|
|
Major Ocular Adverse Events During First Year of Follow-Up
Pseudoendophthalmitis
|
1 Eyes
|
0 Eyes
|
0 Eyes
|
1 Eyes
|
|
Major Ocular Adverse Events During First Year of Follow-Up
Ocular vascular event
|
1 Eyes
|
1 Eyes
|
0 Eyes
|
2 Eyes
|
|
Major Ocular Adverse Events During First Year of Follow-Up
Retinal detachment
|
0 Eyes
|
0 Eyes
|
1 Eyes
|
0 Eyes
|
|
Major Ocular Adverse Events During First Year of Follow-Up
Vitrectomy
|
7 Eyes
|
0 Eyes
|
3 Eyes
|
0 Eyes
|
|
Major Ocular Adverse Events During First Year of Follow-Up
Vitreous hemorrhage
|
15 Eyes
|
3 Eyes
|
4 Eyes
|
2 Eyes
|
|
Major Ocular Adverse Events During First Year of Follow-Up
Increase in intraocular pressure >=10 mmHg
|
16 Eyes
|
10 Eyes
|
5 Eyes
|
70 Eyes
|
|
Major Ocular Adverse Events During First Year of Follow-Up
Intraocular pressure >=30 mmHg
|
3 Eyes
|
2 Eyes
|
4 Eyes
|
46 Eyes
|
|
Major Ocular Adverse Events During First Year of Follow-Up
Initiation of intraocular lowering medication
|
23 Eyes
|
12 Eyes
|
7 Eyes
|
79 Eyes
|
|
Major Ocular Adverse Events During First Year of Follow-Up
Glaucoma surgery
|
0 Eyes
|
0 Eyes
|
0 Eyes
|
0 Eyes
|
|
Major Ocular Adverse Events During First Year of Follow-Up
Cataract surgery
|
11 Eyes
|
6 Eyes
|
8 Eyes
|
19 Eyes
|
Adverse Events
Sham + Prompt Laser
Serious events: 53 serious events
Other events: 139 other events
Deaths: 0 deaths
Ranibizumab + Prompt Laser
Serious events: 46 serious events
Other events: 97 other events
Deaths: 0 deaths
Ranibizumab + Deferred Laser
Serious events: 41 serious events
Other events: 105 other events
Deaths: 0 deaths
Triamcinolone + Prompt Laser
Serious events: 57 serious events
Other events: 145 other events
Deaths: 0 deaths
Sham + Ranibizumab + Laser
Serious events: 21 serious events
Other events: 0 other events
Deaths: 0 deaths
Sham + Ranibizumab + Deferred Laser
Serious events: 20 serious events
Other events: 0 other events
Deaths: 0 deaths
Sham + Triamcinolone + Laser
Serious events: 12 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Sham + Prompt Laser
n=139 participants at risk；n=130 participants at risk
Laser was given within 3 to 10 days after sham injections, Laser = Focal/grid photocoagulation
|
Ranibizumab + Prompt Laser
n=97 participants at risk；n=131 participants at risk
0.5 mg intravitreal ranibizumab plus prompt (within 3-10 days after injection) focal/grid photocoagulation
|
Ranibizumab + Deferred Laser
n=105 participants at risk；n=132 participants at risk
0.5 mg intravitreal ranibizumab with deferred (24 weeks) focal/grid photocoagulation
|
Triamcinolone + Prompt Laser
n=145 participants at risk；n=135 participants at risk
4 mg intravitreal triamcinolone plus prompt (within 3-10 days after injection) focal/grid photocoagulation
|
Sham + Ranibizumab + Laser
n=56 participants at risk
Participants in this group had 2 study eyes, the right eye was assigned randomly with equal probability to one of the four groups (Sham + prompt laser, ranibizumab + prompt laser, ranibizumab + deferred laser, triamcinolone + prompt laser). If the right eye was assigned to a treatment group other than the sham + prompt laser group, then the left eye was assigned to the sham + prompt laser group. If the right eye was assigned to the sham prompt + prompt laser group, then the left eye was assigned randomly to one of the other three groups.
|
Sham + Ranibizumab + Deferred Laser
n=56 participants at risk
Participants in this group had 2 study eyes, the right eye was assigned randomly with equal probability to one of the four groups (Sham + prompt laser, ranibizumab + prompt laser, ranibizumab + deferred laser, triamcinolone + prompt laser). If the right eye was assigned to a treatment group other than the sham + prompt laser group, then the left eye was assigned to the sham + prompt laser group. If the right eye was assigned to the sham prompt + prompt laser group, then the left eye was assigned randomly to one of the other three groups.
|
Sham + Triamcinolone + Laser
n=51 participants at risk
Participants in this group had 2 study eyes, the right eye was assigned randomly with equal probability to one of the four groups (Sham + prompt laser, ranibizumab + prompt laser, ranibizumab + deferred laser, triamcinolone + prompt laser). If the right eye was assigned to a treatment group other than the sham + prompt laser group, then the left eye was assigned to the sham + prompt laser group. If the right eye was assigned to the sham prompt + prompt laser group, then the left eye was assigned randomly to one of the other three groups.
|
|---|---|---|---|---|---|---|---|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Abdominal neoplasm
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Abdominal pain
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Anemia
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Angina pectoris
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Cardiac disorders
Arrhythmia
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Surgical and medical procedures
Arterial bypass operation
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Vascular disorders
Arteriosclerosis coronary artery
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Blood potassium increased
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Reproductive system and breast disorders
Breast cancer
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchitis
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Cardiac disorders
Cardiac failure
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Cardiac disorders
Cardiac failure congestive
|
1.5%
2/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
6.1%
8/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
3.0%
4/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
7.1%
4/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
5.4%
3/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Cardiac disorders
Cardio-respiratory arrest
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Cardiac disorders
Cardiomegaly
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
3.6%
2/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Cellulitis
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Vascular disorders
cerebrovascular accident
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Chest pain
|
3.8%
5/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
2.3%
3/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
3.6%
2/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Convulsion
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Surgical and medical procedures
Coronary arterial stent insertion
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Vascular disorders
Coronary artery disease
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Death
|
1.5%
2/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Dehydration
|
1.5%
2/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Endocrine disorders
Diabetes mellitus
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Endocrine disorders
Diabetes mellitus inadequate control
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
2.0%
1/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Endocrine disorders
Diabetic ketoacidosis
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Dysarthria
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
2.0%
1/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Dyspnoea
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Musculoskeletal and connective tissue disorders
Facial bones fracture
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Gastrointestinal disorders
Food poisoning
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Musculoskeletal and connective tissue disorders
Fracture
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
2.0%
1/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Gastrointestinal disorders
Gastroenteritis
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
2.0%
1/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Gastrointestinal disorders
Gastroesophageal reflux disease
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Goitre
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Haematochezia
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Cardiac disorders
Heart rate increased
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Cardiac disorders
Heart rate irregular
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Hernia
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
2.0%
1/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Hyperglycaemia
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Vascular disorders
Hypertension
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
2.2%
3/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
2.0%
1/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Cardiac disorders
Left ventricular hypertrophy
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Vascular disorders
Hypotension
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Surgical and medical procedures
Hysterectomy
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Gastrointestinal disorders
Impaired gastric emptying
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Infections and infestations
Infection
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Respiratory, thoracic and mediastinal disorders
Influenza
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Vascular disorders
Ischaemic stroke
|
2.3%
3/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Surgical and medical procedures
Knee operation
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
2.0%
1/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Surgical and medical procedures
Leg amputation
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Infections and infestations
Localised infection
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
2.2%
3/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
3.6%
2/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Musculoskeletal and connective tissue disorders
Multiple fractures
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Cardiac disorders
Myocardial infacrtion
|
2.3%
3/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Nervous system disorders
Neuropathy
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Oedema peripheral
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Musculoskeletal and connective tissue disorders
Osteomyelitis
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Pain in extremity
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
2.0%
1/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Vascular disorders
Peripheral vascular disorder
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonia
|
1.5%
2/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Post procedural complications
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Presyncope
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate cancer
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Pulmonary oedema
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Renal and urinary disorders
Renal failure
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
2.3%
3/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
3.6%
2/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
2.0%
1/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Renal and urinary disorders
Renal failure chronic
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Rhabdomyolysis
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Surgical and medical procedures
Shoulder operation
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Skin and subcutaneous tissue disorders
Skin Ulcer
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Surgical and medical procedures
Stent placement
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
2.0%
1/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Syncope
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Cardiac disorders
Tachycardia
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Throat cancer
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Cardiac disorders
Transient ischaemic attack
|
1.5%
2/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Vertigo
|
1.5%
2/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Cataract
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Endophthalmitis
|
1.5%
2/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Intraocular pressure increased
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Retinal vein occlusion
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Vascular disorders
Arterial occlusive disease
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Arthralgia
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Atrial fibrillation
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Anxiety
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Surgical and medical procedures
Biopsy thyroid gland
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Blood glucose decreased
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Boneneoplasm malignant
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Cardiac disorders
Bradycardia
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Cholecystitis acute
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Contusion
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Gastrointestinal disorders
Diverticulitis
|
1.5%
2/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Vascular disorders
Embolism
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Gastrointestinal disorders
Gastric bypass
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Gout
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Hemiparesis
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Musculoskeletal and connective tissue disorders
Hip fracture
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Hypersensitivity
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral disc protrusion
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Respiratory, thoracic and mediastinal disorders
Lung cancer metastatic
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Lymphoedema
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Nausea
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Migraine
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Vascular disorders
Pulmonary embolism
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Renal and urinary disorders
Renal failure acute
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Salivary gland disorder
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Glaucoma
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Iris neovascularisation
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Renal and urinary disorders
Urinary tract infection
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Cardiac disorders
Supraventricular tachycardia
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
hypoglycaemia
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
3.9%
2/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Anaemia of Chronic disease
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Cardiac disorders
Arteriosclerosis coronary artery
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.5%
2/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Joint Injury
|
0.00%
0/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Skin Ulcer
|
0.77%
1/130 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/131 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.76%
1/132 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.74%
1/135 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.8%
1/56 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
0.00%
0/51 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
Other adverse events
| Measure |
Sham + Prompt Laser
n=139 participants at risk；n=130 participants at risk
Laser was given within 3 to 10 days after sham injections, Laser = Focal/grid photocoagulation
|
Ranibizumab + Prompt Laser
n=97 participants at risk；n=131 participants at risk
0.5 mg intravitreal ranibizumab plus prompt (within 3-10 days after injection) focal/grid photocoagulation
|
Ranibizumab + Deferred Laser
n=105 participants at risk；n=132 participants at risk
0.5 mg intravitreal ranibizumab with deferred (24 weeks) focal/grid photocoagulation
|
Triamcinolone + Prompt Laser
n=145 participants at risk；n=135 participants at risk
4 mg intravitreal triamcinolone plus prompt (within 3-10 days after injection) focal/grid photocoagulation
|
Sham + Ranibizumab + Laser
n=56 participants at risk
Participants in this group had 2 study eyes, the right eye was assigned randomly with equal probability to one of the four groups (Sham + prompt laser, ranibizumab + prompt laser, ranibizumab + deferred laser, triamcinolone + prompt laser). If the right eye was assigned to a treatment group other than the sham + prompt laser group, then the left eye was assigned to the sham + prompt laser group. If the right eye was assigned to the sham prompt + prompt laser group, then the left eye was assigned randomly to one of the other three groups.
|
Sham + Ranibizumab + Deferred Laser
n=56 participants at risk
Participants in this group had 2 study eyes, the right eye was assigned randomly with equal probability to one of the four groups (Sham + prompt laser, ranibizumab + prompt laser, ranibizumab + deferred laser, triamcinolone + prompt laser). If the right eye was assigned to a treatment group other than the sham + prompt laser group, then the left eye was assigned to the sham + prompt laser group. If the right eye was assigned to the sham prompt + prompt laser group, then the left eye was assigned randomly to one of the other three groups.
|
Sham + Triamcinolone + Laser
n=51 participants at risk
Participants in this group had 2 study eyes, the right eye was assigned randomly with equal probability to one of the four groups (Sham + prompt laser, ranibizumab + prompt laser, ranibizumab + deferred laser, triamcinolone + prompt laser). If the right eye was assigned to a treatment group other than the sham + prompt laser group, then the left eye was assigned to the sham + prompt laser group. If the right eye was assigned to the sham prompt + prompt laser group, then the left eye was assigned randomly to one of the other three groups.
|
|---|---|---|---|---|---|---|---|
|
Eye disorders
Cataract
|
8.6%
12/139 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
9.3%
9/97 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
9.5%
10/105 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
21.4%
31/145 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Cataract subcapsular
|
5.0%
7/139 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
5.2%
5/97 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
3.8%
4/105 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
15.9%
23/145 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Eye pain
|
15.8%
22/139 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
23.7%
23/97 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
19.0%
20/105 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
8.3%
12/145 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Myodesopsia
|
5.8%
8/139 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
4.1%
4/97 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
9.5%
10/105 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
13.1%
19/145 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Vitreous floaters
|
6.5%
9/139 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
13.4%
13/97 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
10.5%
11/105 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
15.9%
23/145 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Conjunctival haemorrhage
|
2.9%
4/139 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
21.6%
21/97 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
23.8%
25/105 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
11.7%
17/145 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Eye Irritation
|
6.5%
9/139 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
8.2%
8/97 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
10.5%
11/105 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
6.9%
10/145 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Influenza
|
7.2%
10/139 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
6.2%
6/97 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
5.7%
6/105 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
7.6%
11/145 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Intraocular pressure increased
|
5.0%
7/139 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
4.1%
4/97 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
6.7%
7/105 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
37.9%
55/145 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Lacrimation increased
|
6.5%
9/139 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
6.2%
6/97 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
15.2%
16/105 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
3.4%
5/145 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Maculopathy
|
17.3%
24/139 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
12.4%
12/97 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
13.3%
14/105 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
6.2%
9/145 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
General disorders
Nasopharyngitis
|
7.2%
10/139 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
10.3%
10/97 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
9.5%
10/105 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
9.7%
14/145 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Ocular Hyperaemia
|
4.3%
6/139 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
10.3%
10/97 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
4.8%
5/105 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
2.8%
4/145 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Respiratory, thoracic and mediastinal disorders
Upper respiratory tract infection
|
5.8%
8/139 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
12.4%
12/97 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
6.7%
7/105 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
4.1%
6/145 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Vision Blurred
|
28.1%
39/139 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
16.5%
16/97 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
19.0%
20/105 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
22.1%
32/145 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Visual Acuity Reduced
|
9.4%
13/139 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
6.2%
6/97 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
7.6%
8/105 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
7.6%
11/145 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Visual Disturbance
|
9.4%
13/139 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
7.2%
7/97 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
4.8%
5/105 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
9.0%
13/145 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
|
Eye disorders
Vitreous haemorrhage
|
10.8%
15/139 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
3.1%
3/97 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
3.8%
4/105 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
1.4%
2/145 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
—
0/0 • 1 Year
All ocular adverse events are listed under treatment group drug. Participants with a systemic adverse event with two study eyes are listed under the sham/ranibizumab or triamcinolone combination.
|
Additional Information
Adam R. Glassman, Director DRCR.net Coordinating Center
Jaeb Center for Health Research
Phone: 813-975-8690
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place